Given the fact that the growth of the MCF-10A cells was not affected by the combination treatment with Lapatinib and DFP, we concluded that the additive growth inhibitory effect in the HER2+ cell line, HCC-1954, could also be mediated through the STEAP4 pathway inhibition. Here, ERBB2 is linked to hepatocellular carcinoma.